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Abstract
Background: Pathogenesis of inflammatory bowel disease is thought to be through different
factors and there is a relationship between the gut flora and the risk of its development. Probiotics
can manipulate the microflora in chronic inflammation and may be effective in treating inflammation.
Bifidobacterium are saccharolytic and their growth in the gut can be promoted by non-absorbable
carbohydrates and its increase in the colon appears to be of benefit.
Methods: Oligofructose and inulin (OFI) alone and the two B. infantis DSM 15158 and DSM 15159
with and without OFI, were fed to Sprague-Dawley rats for 7 days prior to colitis induction and
administrations continued for another 7 days with the DSS. Colitis severity assessed using a Disease
Activity Index. Samples were collected 7 days after colitis induction, for intestinal bacterial flora,
bacterial translocation, short chain fatty acids (SCFAs), myeloperoxidase (MPO), cytokines (IL-1β,
TNF-α, IL-10 and TGF-β) and malondialdehyde (MDA).
Results: OFI alone or the B. infantis strains with and without OFI improved significantly the DAI
and decreased colonic MPO activity. Colonic tissue IL-1β decreased significantly in all treated
groups except B. infantis DSM 15158. MDA decreased significantly in B. infantis DSM 15159 with
and without OFI compared to colitis control. Succinic acid increased significantly in OFI group with
and without DSM 15159 compared to all groups. Sum values of propionic, succinic acid and butyric
acid increased significantly in all groups compare to the colitis control. Bacterial translocation to
mesenteric lymph nodes decreased significantly in all groups compared to colitis control.
Translocation to the liver decreased significantly in all groups compare to the colitis control and
OFI + B. infantis DSM 15158 groups.
Conclusion: Administrations of OFI and Bifidobacterium improve DSS-induced acute colitis and
have an anti-inflammatory effect. Major differences in effect were observed between the two B.
infantis strains as indicated in MDA and succinic acid concentration as well as bacterial translocation
rate in synbiotic combinations.
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Background
The pathogenesis of inflammatory bowel disease is
thought to involve different factors. The intestinal
mucosal immune system has the formidable task of
remaining unresponsive to the vast indigenous bacterial
population, and yet be able to discriminate and eliminate
pathogenic microorganisms to control infection. Studies
in rodent models [1,2], suggest that abnormalities in this
immuno-bacterial relationship may be a key to the patho-
genesis of the human IBD, ulcerative colitis and Crohn's
disease.
Although not one pathogenic factor has been established,
relationship between the establishment of the gut flora
and the risk of developing inflammatory bowel disease
(IBD) has been suggested [3]. In IBD evidence has been
found for a disturbed balance between pro-inflammatory
and anti-inflammatory cytokines. Increased levels of the
proinflammatory cytokines interleukin-1 (IL-1), IL-6, IL-
8, and tumor necrosis factor α (TNF-α) were detected [4].
The cytokines are secreted by macrophages, lymphocytes,
and polymorphonuclear neutrophils (PMNs) and the
massively infiltrating of these cells are thought to contrib-
ute by producing large amounts of reactive oxygen metab-
olites (ROMs), such as superoxide anion, hydrogen
peroxide, and hypochlorous acid [5].
Probiotics (micro-organism such as bifidobacteria and
lactobacilli with purported physiological benefits) are
being evaluated as an alternative means of manipulating
the microflora in chronic inflammation. Laboratory stud-
ies have shown that probiotics (mainly lactobacilli) may
be effective in treating inflammation [6-8]. Much less
focus has been on bifidobacteria because of cost and
maintenance of viability. In vitro, growth of bifidobacte-
ria can be selectively stimulated by several carbohydrates
indigestible by humans (prebiotics). In particular, the
fructans inulin and oligofructose seem effective at stimu-
lating growth of bifidobacteria selectively in vitro [9].
Consumption of both probiotic bacteria [10], and prebi-
otic components [11], reduces the severity of DSS-
induced colitis.
To clarify the effects and the mechanisms behind we
therefore investigate the efficacy of oral supplementation
of  Bifidobacterium infantis and oligofructose and inulin
(OFI) as a primary prevention and therapy of colitis. We
wanted especially to focus on effects on bacterial translo-
cation, bacterial flora, inflammation, release of oxygen
free radicals and bacterial fermentation.
Methods
Animals and experimental design
Sprague-Dawley rats (200 g) (Möllegård, Viby, Denmark)
were used and divided into six groups (6 animals each),
colitis control and five treatment groups. One group was
treated with a commercially available preparation of oli-
gofructose and inulin (OFI) (Raftilose Synergy 1, Orafti
Active Food ingredients, Tienen, Belgium). This contains
inulin with selected chain lengths from chicory that has
been enriched by a specific fraction of oligofructose pro-
duced by partial enzymatic hydrolysis of chicory inulin.
Four groups were treated with Bifidobacterium infantis (B.
infantis DSM 15158 [= CURE19] or B. infantis DSM 15159
[= CURE21], Probi AB, Lund, Sweden) alone or together
with OFI. The two B. infantis strains have been isolated
from infant feces, and have been selected for their coloni-
zation capabilities and abilities to produce amino acids
from inorganic nitrogen. The animals were kept at room
temperature (22°C) with a controlled 12 hr light/dark
cycle and free access to a standard rat chow (R3; Lactamin,
Stockholm). The experimental solutions were adminis-
tered orally by oro-gastric tube twice daily for 7 days
before starting DSS and continued for 7 days after DSS
induction (probiotics 3 ml; 3 × 106 CFU per animal, preb-
iotics 3 ml; 0.5 g per animal, synbiotics 3 ml; 3 × 106 CFU
+ 0.5 g per animal). Normal saline (3 ml) was adminis-
tered in the colitis control group. Colitis was induced by
5% (w/v) DSS (MW = 36,000–50,000; ICN Biomedicals
Inc., Aurora, OH) dissolved in drinking water for 7 days.
Severity of colitis was assessed daily using a disease activ-
ity index (DAI). After the seventh day of induction of col-
itis, animals were anesthetized with a subcutaneous
injection of a mixture (1:1:2) of Hypnorm (Division of
Janssen-Cilag Ltd., Janssen Pharmaceutica, Beerse, Bel-
gium) + Dormicum (F. Hoffmann-La Roche AG, Basel,
Switzerland) + dH2O at a dose of 0.15 ml/100 g. Under
aseptic technique a laparotomy was performed through a
midline incision and samples were collected for bacterial
microflora (cecum), bacterial translocation (arterial and
portal blood, mesenteric lymph nodes, and liver), SCFAs
(cecal contents), Myeloperoxidase (MPO), cytokines (IL-
1β, TNF-α, IL-10 and TGF-β) and Malondialdehyde
(MDA) (colon tissues). Bacterial microflora samples were
placed immediately in sterile tubes containing, 3 ml of
transport medium, whereas bacterial translocation sam-
ples were placed in sterile tubes containing, 2 ml for
blood, and, 6 m1 for segments [12]. Samples for
cytokines, MPO, MDA, and SCFAs were immediately fro-
zen at -70°C. The experimental design was approved by
the Animal Ethics Committee of Lund University and the
experiments adhered to the guiding principles in the care
and use of animals.
Assessment of colitis
The severity of colitis was assessed daily using a Disease
Activity Index (DAI) based on the scoring system of
Murthy et al. [13,14], which scores body weight loss, stool
consistency, and rectal bleeding. Occult blood in feces was
evaluated by means of test slides, Hemoccult II (SmithK-BMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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line Diagnostic, USA). The DAI clinical parameters used
here are comprehensive functional measures that are
somewhat analogous to clinical symptoms observed in
human IBD and the scoring method has been validated by
repeated studies [15].
Bacterial translocation
Samples from the caudate lobe of liver, mesenteric lymph
nodes, portal and arterial blood were placed in an ultra-
sonic bath (Millipore, Sundbyberg, Sweden) for 5 min
and swirled on Chiltern (Therma-Glas, Gothenberg, Swe-
den) for 2 min. Viable counts were obtained from brain
heart infusion (BHI) agar (Difco, Detroit, MI) that was
incubated aerobically and under anaerobic condition
(Gas Pack System, Gas Pack; Becton Dickenson Microbiol-
ogy Systems, Cockeynsville, MD) at 37°C for 72 h (aero-
bic and anaerobic bacterial count, respectively). Violet-red
bile glucose (VRBG) agar (Oxoid) was incubated aerobi-
cally at 37°C for 24 h (Enterobacteriaceae  count). The
number of colonies formed on each plate was counted
and corrected for the weight of the original tissue and vol-
ume of blood. Tissue samples are expressed per gram of
tissue while blood samples are expressed per milliliter of
blood.
Intestinal microflora
The samples from the cecum were placed in an ultrasonic
bath and swirled on Chiltern as above. A conventional
dilution procedure was done. Viable counts were
obtained from BHI agar that was incubated aerobically
and anaerobically at 37°C for 72 h (aerobic and anaerobic
bacterial count, respectively), Rogosa agar (Oxoid) that
was incubated anaerobically at 37°C for 72 h (lactobacilli
count), from VRBG agar (Oxoid) that was incubated aero-
bically at 37°C for 24 h (Enterobacteriaceae count), and
from the selective media, Modified Wilkins-Chalgren agar
(MW; Oxoid), Modified Trypticase phytone-yeast extract
agar (MTPY; ACSA, Spain) [16] and non-strictly selective
Basic nutrient-poor media [17], which was modified
according to the following composition per liter, (sodium
acetate 10 g: ascorbic acid 10 g: (NH4)2SO4 5 g: K2HPO4 3
g: (KH)2PO4 3 g: tween 80 1 ml: yeast extract 0.5 g: glucose
20 g: agar 15 g and 5 ml of the mineral salt solution which
composed per 250 ml of(MgSO4·7H2O 16 g:
FeSO4·7H2O 0.5 g: MnSO4·H2O 0.35 g: NaCl 0.5 g) pH
6.18–6.24. They were incubated under anaerobic condi-
tions at 37°C for 72 h (bifidobacteria count).
Cytokines
Samples of colon were weighed and homogenized for 1
min in phosphate buffer. The homogenates were centri-
fuged at 10 000 g at 4°C for 5 min. TNF-α, IL-1β, IL-10
and TGF-β concentration in the supernatants were deter-
mined by ELISA using the commercially available Quan-
tikine kit (R&D Systems, Minneapolis, MN 55413, USA).
Optical densities were measured on an ELISA reader at a
wavelength of 450 nm. Data were analyzed against the
linear portion of the generated standard curve.
Myeloperoxidase (MPO)
Colonic tissues were collected, weighed prior to storage at
-70°C until time of assay for MPO activity. The colonic
segments were homogenized in 1 ml potassium phos-
phate buffer (20 mM, pH 7.4) for 60 sec. Subsequently,
the homogenate was centrifuged (14000 rpm, 10 min)
and the pellet was resuspended in 1 ml potassium phos-
phate buffer (50 mM, pH 6.0) containing 0.5% hexadecyl-
trimethyl-ammonium bromide. The sample was then
freeze thawed once, sonicated (90 sec) and kept in water
bath for 120 min (60°C). Next, the sample was centri-
fuged (14000 rpm, 10 min) and the MPO activity of the
supernatant (20 µl) assessed in 96-well plates (Nunc, Inv-
itrogen A/S, Taastrup, Denmark). The enzyme activity was
determined spectrophotometrically at 450 nm. MPO
(Sigma Chemical Co., St. Louis, MO, USA) was used as
standard and values are expressed as MPO units g-1 tissue.
Lipid peroxidation
Malondialdehyde (MDA) were determined as index of
lipid peroxidation, using MDA 586™ (R&D, Europe Ltd,
Abingdon, Oxon, UK). Colonic segments were collected,
rinsed in ice cold Dulbecco's PBS, weighed and then fro-
zen immediately at -70°C for later evaluation. Lipid per-
oxidation was estimated by adding 1 ml Dulbecco's PBS
with 5 mM butylated-hydroxyltoluene to the samples and
then homogenized. After homogenization the samples
were centrifuged at 4000 × g for 10 minutes (min) at 4°C.
An aliquot (200 µl) of the standard and/or the superna-
tant was added to a reaction mixture containing 640 µl of
N-methyl-2-phelindole, 10 µl probucol and 150 µl of 12
M hydrochloric acid. The samples were then incubated in
a water bath for 60 min at 45°C and centrifuged at 10000
× g for 10 min at 4°C. The absorbance of the standard and
supernatant was measured by Spectrophotometry at 586
nm. The results were expressed as nmol MDA/g tissue.
Short Chain Fatty Acids (SCFAs)
SCFAs and organic acids (lactic, and succinic, acid) were
measured by a modification of the capillary GC method
by Richardson et al. [18] as described by Jensen et al. [19].
Sample preparation was done by diluting 10 times the
cecal content samples with a working solution containing
water and internal standard (IS) (100 mmol/l 2-Ethylbu-
tyric acid). The diluted sample was homogenized and a 1
ml sub-sample was taken for extraction. This sample was
extracted by adding 0.1 ml H2O, 500 µl hydrochloric acid
(HCl) and 2000 µl ether followed by mixing for 30 sec-
onds on a Vibrax at 1400 rpm, and centrifugation for 10
min at 3000 g. For every 8 samples, 2 standard mixtures
were prepared by adding 0.1 ml H2O, 0.5 ml HCl, 100 µlBMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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working solution and 2000 µl ether to a 1 ml standard
mixture. To the GC microvial was added 50 µl sample
and/or standard from the ether-phase together with 10 µl
N-tert-butyldimethylsilyl-N-trifluoroacetamid, to deriva-
tize the samples and get volatile and thermal constant
derivatives that are suitable for GC run. The vial with
Crimp-Caps were closed and mixed once and placed on
the 80°C heating block for 20 minutes. To complete the
derivatisation, the samples were allowed to stand 48
hours before injection. The analysis was performed using
a gas chromatograph provided with capillary column
(DB-5, J&W Scientific, USA). The following temperature-
program were used (70°C (3 min), 70–110°C (10°C/
min), 110–270°C (20°C/min). Detector and injector
temperature were 275 and 300°C, respectively, and the
carrier gas was helium (1.9 ml/min). 2 µl sample volume
was injected.
Statistics
Values are presented as mean ± SEM or as median (10th,
25th, 75th, and 90th percentiles). For the DAI the differ-
ence between the groups was evaluated using Kruskal-
Wallis one-way ANOVA on ranks followed by all-pairwise
multiple comparison procedures (Student-Newman-
Keuls Method). Bacterial translocations and intestinal
microflora were evaluated by one-way ANOVA followed
by all-pairwise multiple comparison procedures (Student-
Newman-Keuls Method). For cytokines, MPO, and MDA
the difference between the groups was evaluated using
one-way ANOVA followed by multiple-comparison ver-
sus control-group Dunnett's method. Probability levels of
<0.05 were considered significant (p < 0.05).
Results
Assessment of disease activity index DAI
There was no mortality among the experimental groups.
DAI decreased significantly on day 4 & 5 (data not shown)
and day 6 & 7 in all groups compared to colitis control
group (Figure 1).
Bacterial translocation
Bacterial translocation to the liver decreased significantly
in all the groups compared to colitis control and OFI + B.
infantis DSM 15158 groups (Table 1). Bacterial transloca-
tion to the mesenteric lymph nods decreased significantly
in all the groups compared to colitis control (Table 1).
Intestinal bacterial flora
The bifidobacterial counts in cecum (using 2 selective
media) increased significantly in the OFI groups with and
without added B. infants compared to colitis control (8.74
± 0.07, 8.89 ± 0.16, 8.32 ± 0.50 versus 6.82 ± 0.37 for the
modified Wilkins-Chalgren agar) and (8.73 ± 0.07, 8.60 ±
0.19, 8.23 ± 0.48 versus 6.57 ± 0.37 for the modified Tryp-
ticase phytone-yeast extract agar). For the not strictly selec-
tive media it increased significantly in all groups
compared to colitis control (Data not shown). There were
no differences in the cecum Enterobacteriaceae count. The
cecal count of lactobacilli increased significantly in B.
infantis DSM 15159 groups with and without OFI (8.85 ±
0.24 and 9.56 ± 0.05 respectively) compared to colitis
control (7.82 ± 0.47).
Myeloperoxidase (MPO)
Colonic myeloperoxidase activity decreased significantly
in all groups compared to the colitis control group (Figure
2).
Cytokines
Colonic tissue IL-1β decreased significantly in all treated
groups except B. infantis DSM 15158 (Figure 3), while lev-
els of TGF-β and IL-10 were maintained in all groups with-
out significant difference (data not shown). There was no
detection of TNF-α in any of the groups.
Lipid peroxidation
MDA decreased significantly in the B. infantis DSM 15159
groups with and without OFI compared to colitis control
(Figure 4).
Short-Chain Fatty Acids (SCFAs)
Succinic acid increased significantly in the OFI groups
with and without DSM 15159 compared to the control
and other groups (Table 2). Sum values of propionic and
butyric acid increased significantly in all treated groups
[5.9 (3.9–7.3), 6.1(4.1–8.6), 4.7(3.3–6.5), 5.7(4.5–6.4),
6.4(4.6–10.1)] compare to the colitis control group
[3.2(2.3–3.8)]. Sum values of succinic, propionic and
butyric acids also increased significantly in all treated
groups [5.4 (3.6–7.0), 4.1(0.0–6.6), 3.3(1.6–5.2),
4.9(3.0–5.8), 6.0(4.0–10.0)] compare to the colitis con-
trol group [2.6(0.0–3.3)], but the OFI + B. infantis DSM
15159 was significantly higher [6.0(4.0–10.0)] than in all
other groups.
Discussion
Daily oral administration of Bifidobacteria, oligufructose
and inulin produced an anti-inflammatory effect in a rat
model of acute colitis induced by DSS. The effect of OFI,
B. infantis DSM 15158 and B. infantis DSM 15159 both
separately and in combination were characterized by a
reduction in DAI. It has previously been shown in a pilot
study that short term treatment of active UC with bifido-
bacterium longum and Synergy 1 resulted in improvement
of chronic inflammation in patients [20]. The results of
that study dose not evaluate production of SCFA or if the
different bifidobacteria have similar action. We have cho-
sen Bifidobacterium infantis, which was isolated from feces
of healthy infants. We believe that the bacterial strains
that are colonizing gut of the newborn infant have specificBMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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characteristics that may also benefit adult mucosa that is
under inflammatory stress.
Both bacteria as well as the fiber component were effective
in reducing colonic disease activity index, although DSM
15159 seemed superior. The same holds true for bacterial
translocation where DSM 15159 was superior in reducing
bacterial translocation to both liver and mesenteric lymph
nodes in synbiotic combination. We found that tissue
MPO activity as an index of neutrophil infiltration signif-
icantly reduced in all groups compare to the colitis con-
trol. However, the observed anti-inflammatory effect may
have been reached through different mechanisms.
The increase of IL-1β in the colitis group was significantly
decreased in all groups except in the B. infantis DSM
15158 group. The expression of IL-1 is increased in
inflammatory lesions of patients with IBD (4) and IL-1 is
involved in the development of DSS-induced colitis in
mice [21]. The reduction of IL-1β could be achieved
through different ways. Incubation of mucosal explants
from Crohn's disease patients showed that certain probi-
otic bacteria are capable of interacting with immunocom-
petent cells and modulate locally the production of
proinflammatory cytokines by inflamed tissue [22]. A
human epithelial cell line HT29/19A, which produces the
chemokines IL-8, upon stimulation with IL-1, TNF and
interferon when incubated with bacterial cell suspensions
showed that Gram-positive probiotic bacteria did not
Disease activity index on day 6 and 7 Figure 1
Disease activity index on day 6 and 7. Values are shown as box plots because the data were not normally distributed. The 
center line of each box represents the median, the top and bottom of the boxes represent the 25th and 75th percentile of the 
data, respectively, and the top and the bottom of the error bars represent the 10th and the 90th percentile of the data respec-
tively. * denotes p < 0.05 compared to colitis control.BMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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Table 1: Bacterial translocation count to the liver and mysenteric lymph nodes (MLNs) (log CFU/g tissue) and Incidence of 
translocation
Aerobic Anaerobic Enterobacteriaceae
Liver
Colitis control 2.72 ± 0.77 (4/6) 3.58 ± 0.33 (5/6) 1.89 ± 0.66 (4/6)
OFI 0.38 ± 0.38 * # (1/6) 0.50 ± 0.50 * # (1/6) 0.00 ± 0.00 * # (0/6)
DSM 15158 0.00 ± 0.00 * # (0/6) 0.00 ± 0.00 * # (0/6) 0.00 ± 0.00 * # (0/6)
OFI + DSM 15158 3.14 ± 1.01 (4/6) 3.29 ± 1.06 (4/6) 2.98 ± 0.73 (4/6)
DSM 15159 0.55 ± 0.55 * # (1/6) 0.57 ± 0.57 * # (1/6) 0.00 ± 0.00 * # (0/6)
OFI + DSM 15159 0.00 ± 0.00 * # (0/6) 0.00 ± 0.00 * # (0/6) 0.00 ± 0.00 * # (0/6)
MLNs
Colitis control 2.61 ± 0.76 (4/6) 2.71 ± 0.80 (4/6) 1.73 ± 0.73 (3/6)
OFI 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6)
DSM 15158 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6)
OFI + DSM 15158 0.48 ± 0.48 * (1/6) 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6)
DSM 15159 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6)
OFI + DSM 15159 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6) 0.00 ± 0.00 * (0/6)
* denotes p < 0.05 compared to colitis control, # denotes p < 0.05 compared to OFI + DSM 15158 group, OFI = Oligofructose and Inulin. 
Incidence of translocation is presented between parentheses as positive animals/total number of animals.
Colonic Myeloperoxidase Activities (U/g tissue) Figure 2
Colonic Myeloperoxidase Activities (U/g tissue). * denotes p < 0.05 compared to colitis control.BMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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induce IL-8 production, whereas the non pathogenic
Gram-negative strain did in a dose-dependent way [23]. It
has been shown that butyrate significantly inhibits Th1-
type responses and that this might explain the therapeutic
effect of butyrate in IBD patients. Acetate and propionate
have less marked modulatory actions, and in some cases
have effects that oppose those of butyrate. A combination
of the three SCFA causes a shift in the T helper lymphocyte
phenotype towards a more anti-inflammatory phenotype
[24], and in this study we found that succinic acid
increased significantly in OFI group with and without
DSM 15159 compared to the colitis control and other
groups and the sum values of propionic, butyric and suc-
cinic acid increased significantly in all treated groups com-
pared to the colitis control group. However, this might
explain that the protective effects of prebiotics and probi-
otics could be through the production of SCFAs.
The production of TNF-α was not detected in all our
groups. We can not for sure conclude or suggest that TNF-
α has no role in intestinal inflammation. The lack of
detection in our experiment could be due to the sensitivity
of the ELISA kit. Also reports of this cytokine in inflamma-
tory bowel disease IBD are somewhat contradictory,
whereas some groups were able to demonstrate increased
levels of TNF others were unable to detect it in patients
with IBD (4). In another animal study, failure to detect
local or systemic TNF and failure to prevent colonic
inflammation with anti-TNF antiserum have pointed that
TNF could not be an inflammatory mediator in DSS-
induced murine colitis (25). IL-10 and TGF-β were main-
tained in all groups and this suggests that mediators other
than them are involved in the anti-inflammatory effects.
These results are in agreement with a previous study [7].
On the other hand, studies of IL-10 levels in inflamed
mucosa are not conclusive. Preliminary data from previ-
ous researchers indicate that a feed back loop may exist in
IBD, in which an increased production of the cytokine
interferon-γ down regulates IL-10 production, therefore
its level in the mucosa may be (although increased) not
adequately high [26]. Topical IL-10 enema treatment of
patients with ulcerative colitis unveiled that IL-10 is effec-
tive in down-regulating pro-inflammatory cytokine syn-
thesis from IBD monocytes and lymphocytes both in vitro
and in vivo [27]. In that study, equal concentrations of IL-
10 appear detectable in both normal and IBD intestinal
Colonic IL-1β values (pg/g tissue) Figure 3
Colonic IL-1β values (pg/g tissue). * denotes p < 0.05 compared to colitis control.BMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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lamina propria biopsy homogenates. This seems surpris-
ing in view of other results [28,29] also argue against a
general deficiency in IL-10 production in IBD. They in fact
observed an increase in IL-10 producing cells and rather
suggest that in IBD the production of IL-10 is dislocated
and insufficient to down-regulate pro-inflammatory
cytokines in the lamina propria compartment. It has also
bean shown that IL-10 gene therapy is therapeutic for dex-
tran sodium sulfate-induced murine colitis [30].
Oxidative stress has been implicated in the pathogenesis
of inflammatory bowel disease. Enhanced release of reac-
tive oxygen species (ROS) plays an important role in the
pathogenesis of clinical inflammatory bowel diseases.
ROS are also involved in the pathogenesis of DSS-induced
colitis [31]. In the IBD patients serum lipid peroxidation
products were significantly elevated when compared to
control subjects, suggesting the presence of increased oxi-
dative stress consistent with inflammatory activity [32]. It
has been shown that measurements of lipid peroxidation
confirm previous evidence, indicating that development
of colitis is associated with a significant burst in ROS [33].
We measured MDA in colonic tissues as an assessment of
oxidative stress. We found significantly decreased levels of
mucosal lipid peroxidation products in the B.  infantis
DSM 15159 groups with and without OFI compared to
the colitis group. This is consistent with findings in other
studies showing an increased in lipid peroxidation prod-
ucts with inflammation, both in Crohn's disease and
ulcerative colitis [34]. We also found that there was
increase in succinic acid in B. infantis DSM 15159 + OFI
group. Because of the pH-depended inhibition of the res-
Malondialdehyde (MDA) concentration in the colon (nmol/g tissue) Figure 4
Malondialdehyde (MDA) concentration in the colon (nmol/g tissue). * denotes p < 0.05 compared to colitis control.
Table 2: SCFAs values (µmol/g cecal content) of all the experimental groups
SCFAs Colitis Control OFI DSM 15158 OFI + DSM 15158 DSM 15159 OFI + DSM 15159
Succinic 0.0 (0.0–1.1) 4.5 (2.9–5.7) * 0.0 (0.0–0.0) # § 1.5 (1.2–1.6) # § 0.4 (0.0–4.7) # § 5.9 (4.0–6.8) *
Propionic 3.3 (3.1–3.3) 6.2 (3.6–7.0) 4.7 (3.2–5.7) 4.9 (4.7–8.8) 5.7 (5.1–5.9) 7.5 (5.9–10.3)
Butyric 2.3 (0.0–8.4) 5.5 (4.2–7.6) 6.8 (6.4–13.7) 3.3 (3.1–6.2) 5.7 (3.9–6.8) 5.9 (3.3–10.0)
Acetic 23.1 (22.7–28.1) 35.8 (26.1–47.1) 30.9 (24.7–46.3) 20.0 (18.6–25.3) 22.9 (20.7–28.3) 28.4 (20.8–36.8)
Lactic 0.0 (0.0–0.0) 1.6 (0.0–3.2) 2.5 (2.4–3.0) 0.4 (0.0–1.1) 0.4 (0.0–1.0) 2.0 (0.0–2.8)
* denotes p < 0.05 compared to colitis control; # denotes p < 0.05 compared to OFI + DSM 15159; § denotes p < 0.05 compared to OFI. Data 
presented as Median (25th–75th percentile)BMC Gastroenterology 2006, 6:31 http://www.biomedcentral.com/1471-230X/6/31
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piratory burst by succinate [35], this increase could cause
a significant reduction in pH, thereby succinic acid may be
by reducing pH further reduce neutrophils infiltration and
the neutrophil respiratory burst [35].
B. infantis DSM 15159 with and without OFI increased
significantly cecum lactobacilli count, which might sug-
gest that the reduction of lipid peroxidation might also be
caused by the formation of antioxidant factors by lactoba-
cilli. Cecum bifidobacteria count increased significantly
in OFI with and without B. infantis strains and this is prob-
ably due to the fact that bifidobacteria utilized OFI rapidly
and increased in numbers. Wang et al (9) showed that oli-
gofructose and inulin selectively stimulated growth of
bifidobacteria. Bacterial translocation has been reduced
by most of the groups to MLNs and liver. In MLNs the
increased translocation in DSS-colitis decreased signifi-
cantly in all treated groups. As for the liver, the transloca-
tion decreased significantly in all groups compare to the
colitis group and OFI + B. infantis DSM 15158 groups.
This reduction in bacterial translocation could be due to
the reduction in the inflammation by the different mech-
anisms mentioned before. It seems that the translocation
to the extraintestinal sites is affected by the administration
of pre- and probiotic and this could be due to the effects
on gastrointestinal tract, barrier functions and intestinal
inflammation. These have been reflected by the reduction
of IL-1β, MPO and MDA in the intestinal tissue, and
reduction of disease activity index.
Conclusion
Major differences in effect were observed between the two
tested strains of B. infantis with regards to MDA, succinic
acid concentration and translocation rate. The mecha-
nisms by which probiotics, prebiotics and synbiotics work
and affect the colitis induced by DSS could be through
direct and indirect effects on microflora ecology, barrier
functions and cellular proliferation, and production of
different substances e.g. SCFAs, which could affect the
local and systemic immunity and lipid peroxidation.
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